Treatment of Schizophrenic Patients With Ziprasidone
TRITON
1 other identifier
observational
450
1 country
20
Brief Summary
To determine whether ziprasidone provides good efficacy and tolerability in the treatment of schizophrenic Greek patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2007
20 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2007
CompletedFirst Submitted
Initial submission to the registry
December 20, 2007
CompletedFirst Posted
Study publicly available on registry
December 24, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2009
CompletedResults Posted
Study results publicly available
May 17, 2010
CompletedMarch 10, 2021
February 1, 2021
1.5 years
December 20, 2007
April 2, 2010
February 18, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Summary of Schizophrenia
Stage, symptoms and type of schizophrenia were recorded in addition to demographic and other clinical history data at the Baseline visit. The primary outcome was to assess the participants profile. Some assessments have been included in the Baseline demographics. This outcome presents results for the Summary of Schizophrenia.
Baseline
Summary of Metabolic Risk Factors
Baseline
Summary of Most Frequently Used Concomitant Drug Treatments
Most frequently concomitant drug treatments used by \>15 participants.
Baseline
Secondary Outcomes (20)
Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I)
Week 12
Number of Participants With Categorical Scores on Clinical Global Impression of Severity (CGI-S)
Baseline, Week 12
Positive and Negative Syndrome Scale (PANSS) - Positive Subscale
Baseline, Week 12
PANSS - Negative Subscale
Baseline, Week 12
PANSS - Composite Subscale
Baseline, Week 12
- +15 more secondary outcomes
Other Outcomes (1)
Number of Participants Continuing Treatment With Ziprasidone Following Completion of the Observation Period
Week 12
Interventions
Ziprasidone 20mg, 40mg, 60mg, 80mg capsules, hard; Ziprasidone 10 mg/ml oral suspension Ziprasidone 20mg/ml powder and solvent for the reconstitution of solution for injection
Eligibility Criteria
Patients diagnosed with schizophrenia
You may qualify if:
- Usual clinical practice of physician
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (20)
Pfizer Investigational Site
Athens, 12461, Greece
Pfizer Investigational Site
Chaïdári, 124 61, Greece
Pfizer Investigational Site
Chaïdári, 12461, Greece
Pfizer Investigational Site
Chaïdári, 12462, Greece
Pfizer Investigational Site
Corfu, 49100, Greece
Pfizer Investigational Site
Crete, 731-00, Greece
Pfizer Investigational Site
Giannitsá, 58100, Greece
Pfizer Investigational Site
Haidari, 12461, Greece
Pfizer Investigational Site
Kalamata, 24100, Greece
Pfizer Investigational Site
Katerini, 60100, Greece
Pfizer Investigational Site
Kozani, 50100, Greece
Pfizer Investigational Site
Kozani, Greece
Pfizer Investigational Site
Lamia, 35100, Greece
Pfizer Investigational Site
Larissa, Greece
Pfizer Investigational Site
Pátrai, 26000, Greece
Pfizer Investigational Site
Pátrai, 26001, Greece
Pfizer Investigational Site
Thessaloniki, 564-29, Greece
Pfizer Investigational Site
Thessaloniki, 56430, Greece
Pfizer Investigational Site
Thessaloniki, 57010, Greece
Pfizer Investigational Site
Volos, 38222, Greece
Related Publications (1)
Wang Z, Pang C, Meng Q, Zhang DZ, Hong ZX, He GB, Yang H, Xiang BD, Li X, Jiang TA, Li K, Tang Z, Huang F, Lu M, Yu XL, Cheng ZG, Liu FY, Han ZY, Dou JP, Wu SS, Yu J, Liang P. Laparoscopic hepatectomy versus microwave ablation for multifocal 3-5 cm hepatocellular carcinoma: a multi-centre, real-world study. Int J Surg. 2024 Nov 1;110(11):6911-6921. doi: 10.1097/JS9.0000000000001398.
PMID: 39699863DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Limitations and Caveats
Additional descriptive tables were identified as required after review of the originally planned study tables; many subjects included in the tables had received ziprasidone doses above those specified in the summary of product characteristics (SmPC).
Results Point of Contact
- Title
- Pfizer ClinicalTrials.gov Call Center
- Organization
- Pfizer, Inc.
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 20, 2007
First Posted
December 24, 2007
Study Start
October 1, 2007
Primary Completion
April 1, 2009
Study Completion
April 1, 2009
Last Updated
March 10, 2021
Results First Posted
May 17, 2010
Record last verified: 2021-02